Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia

Nasim Sheikh-Bahaei, Seyed Ahmad Sajjadi, Aimee Pierce

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Purpose of review Alzheimer’s disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI. However, there are certain circumstances wherein detection of specific biomarkers of neurodegeneration or underlying AD pathology will impact the clinical diagnosis or treatment plan. We will review the currently available biomarkers for AD and frontotemporal dementia (FTD) and discuss their clinical importance. Recent findings With the advent of 18F-labeled tracers that bind amyloid plaques, amyloid PET is now clinically available for the detection of amyloid pathology and to aid in a biomarker-supported diagnosis of AD or mild cognitive impairment (MCI) due to AD. It is not yet possible to test for the specific FTD pathologies (tau or TDP-43); however, a diagnosis of FTD may be “imaging supported” based upon specific MRI or FDG-PET findings. Cerebrospinal fluid measures of amyloid-beta, total-tau, and phospho-tau are clinically available and allow detection of both of the cardinal pathologies of AD: amyloid and tau pathology. Summary It is appropriate to pursue biomarker testing in cases of MCI and dementia when there remains diagnostic uncertainty and the result will impact diagnosis or treatment. Practically speaking, due to the rising prevalence of amyloid positivity with advancing age, measurement of biomarkers in cases of MCI and dementia is most helpful in early-onset patients, patients with atypical clinical presentations, or when considering referral for AD clinical trials.

Original languageEnglish (US)
Article number46
JournalCurrent Treatment Options in Neurology
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2017
Externally publishedYes

Fingerprint

Frontotemporal Dementia
Alzheimer Disease
Biomarkers
Amyloid
Pathology
Dementia
Amyloid Plaques
Neurologic Examination
Uncertainty
Cerebrospinal Fluid
Referral and Consultation
Clinical Trials

Keywords

  • Alzheimer’s disease
  • Clinical diagnosis
  • Frontotemporal dementia
  • Frontotemporal lobar degeneration
  • Imaging biomarkers

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia. / Sheikh-Bahaei, Nasim; Sajjadi, Seyed Ahmad; Pierce, Aimee.

In: Current Treatment Options in Neurology, Vol. 19, No. 12, 46, 01.12.2017.

Research output: Contribution to journalReview article

@article{587fea1e73af4242b886d5329563c4aa,
title = "Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia",
abstract = "Purpose of review Alzheimer’s disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI. However, there are certain circumstances wherein detection of specific biomarkers of neurodegeneration or underlying AD pathology will impact the clinical diagnosis or treatment plan. We will review the currently available biomarkers for AD and frontotemporal dementia (FTD) and discuss their clinical importance. Recent findings With the advent of 18F-labeled tracers that bind amyloid plaques, amyloid PET is now clinically available for the detection of amyloid pathology and to aid in a biomarker-supported diagnosis of AD or mild cognitive impairment (MCI) due to AD. It is not yet possible to test for the specific FTD pathologies (tau or TDP-43); however, a diagnosis of FTD may be “imaging supported” based upon specific MRI or FDG-PET findings. Cerebrospinal fluid measures of amyloid-beta, total-tau, and phospho-tau are clinically available and allow detection of both of the cardinal pathologies of AD: amyloid and tau pathology. Summary It is appropriate to pursue biomarker testing in cases of MCI and dementia when there remains diagnostic uncertainty and the result will impact diagnosis or treatment. Practically speaking, due to the rising prevalence of amyloid positivity with advancing age, measurement of biomarkers in cases of MCI and dementia is most helpful in early-onset patients, patients with atypical clinical presentations, or when considering referral for AD clinical trials.",
keywords = "Alzheimer’s disease, Clinical diagnosis, Frontotemporal dementia, Frontotemporal lobar degeneration, Imaging biomarkers",
author = "Nasim Sheikh-Bahaei and Sajjadi, {Seyed Ahmad} and Aimee Pierce",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s11940-017-0484-z",
language = "English (US)",
volume = "19",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "12",

}

TY - JOUR

T1 - Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia

AU - Sheikh-Bahaei, Nasim

AU - Sajjadi, Seyed Ahmad

AU - Pierce, Aimee

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose of review Alzheimer’s disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI. However, there are certain circumstances wherein detection of specific biomarkers of neurodegeneration or underlying AD pathology will impact the clinical diagnosis or treatment plan. We will review the currently available biomarkers for AD and frontotemporal dementia (FTD) and discuss their clinical importance. Recent findings With the advent of 18F-labeled tracers that bind amyloid plaques, amyloid PET is now clinically available for the detection of amyloid pathology and to aid in a biomarker-supported diagnosis of AD or mild cognitive impairment (MCI) due to AD. It is not yet possible to test for the specific FTD pathologies (tau or TDP-43); however, a diagnosis of FTD may be “imaging supported” based upon specific MRI or FDG-PET findings. Cerebrospinal fluid measures of amyloid-beta, total-tau, and phospho-tau are clinically available and allow detection of both of the cardinal pathologies of AD: amyloid and tau pathology. Summary It is appropriate to pursue biomarker testing in cases of MCI and dementia when there remains diagnostic uncertainty and the result will impact diagnosis or treatment. Practically speaking, due to the rising prevalence of amyloid positivity with advancing age, measurement of biomarkers in cases of MCI and dementia is most helpful in early-onset patients, patients with atypical clinical presentations, or when considering referral for AD clinical trials.

AB - Purpose of review Alzheimer’s disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI. However, there are certain circumstances wherein detection of specific biomarkers of neurodegeneration or underlying AD pathology will impact the clinical diagnosis or treatment plan. We will review the currently available biomarkers for AD and frontotemporal dementia (FTD) and discuss their clinical importance. Recent findings With the advent of 18F-labeled tracers that bind amyloid plaques, amyloid PET is now clinically available for the detection of amyloid pathology and to aid in a biomarker-supported diagnosis of AD or mild cognitive impairment (MCI) due to AD. It is not yet possible to test for the specific FTD pathologies (tau or TDP-43); however, a diagnosis of FTD may be “imaging supported” based upon specific MRI or FDG-PET findings. Cerebrospinal fluid measures of amyloid-beta, total-tau, and phospho-tau are clinically available and allow detection of both of the cardinal pathologies of AD: amyloid and tau pathology. Summary It is appropriate to pursue biomarker testing in cases of MCI and dementia when there remains diagnostic uncertainty and the result will impact diagnosis or treatment. Practically speaking, due to the rising prevalence of amyloid positivity with advancing age, measurement of biomarkers in cases of MCI and dementia is most helpful in early-onset patients, patients with atypical clinical presentations, or when considering referral for AD clinical trials.

KW - Alzheimer’s disease

KW - Clinical diagnosis

KW - Frontotemporal dementia

KW - Frontotemporal lobar degeneration

KW - Imaging biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85034949159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034949159&partnerID=8YFLogxK

U2 - 10.1007/s11940-017-0484-z

DO - 10.1007/s11940-017-0484-z

M3 - Review article

AN - SCOPUS:85034949159

VL - 19

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 12

M1 - 46

ER -